Screener
BridgeBio Pharma BBIO Professional service fees
Professional service fees at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:AccruedProfessionalFeesCurrent.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Accrued rebates and other related costs | $59,784 | $45,909 |
| Accrued commercial | 36,963 | 35,773 |
| Deferred royalty obligations, current portion (1) | 21,488 | 11,221 |
| Accrued professional services | 7,540 | 3,665 |
| Accrued interest | 5,188 | 14,411 |
| Other accrued liabilities | 4,546 | 9,243 |
| Total other current liabilities | $135,509 | $120,222 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's professional service fees?
- BridgeBio Pharma (BBIO) reported professional service fees of $7.54M in Q1 2026.
- What is the long-term trend for BridgeBio Pharma's professional service fees?
- Over 4 years (2020 to 2025), BridgeBio Pharma's professional service fees has grown at a -10.0% compound annual growth rate (CAGR), from $5.58M to $3.67M.
Ask your AI about BridgeBio Pharma's professional service fees.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude